Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Transcription factors binding to the promoter of TGFB1 identified by mass spectrometry–based DNA-protein interaction screening.
  • Fig. S2. Expression of YY1 in male and female db/db mice at different time periods.
  • Fig. S3. Transmission electron microscopy analysis of glomerular lesions in the kidneys of control and 5/6 Nx mice.
  • Fig. S4. The effects of siNrf2 alone or in combination with siYY1 on the transcriptional activity of TGFB1 in HRMCs.
  • Fig. S5. Pharmacological activation of endogenous YY1 protects mouse kidneys from diabetic lesion development.
  • Fig. S6. Off-target effects and toxicity analysis of EDN in the regulation of DN progression.
  • Fig. S7. Intervention of EDN in db/db mice ameliorates DN progression.
  • Fig. S8. A graphical abstract of this study.
  • Table S1. Clinical characteristics of DN in biopsy samples.
  • Table S2. List of the compounds that increased the luciferase activity of YY1 but decreased that of TGFB1.
  • Table S3. The sequences of siRNAs used.
  • Table S4. Primers used in DNA pull-down assays.
  • Table S5. Primers used in qRT-PCR.
  • Table S6. Primers used in ChIP assays and site-directed mutagenesis assays.
  • Table S7. Primers used in EMSA.
  • Legends for data files S1 and S2

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Raw data from mass spectrometry analysis.
  • Data file S2 (Microsoft Excel format). Data plotted in figures.